AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 9616529 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 426
Study 7616869 — intervention group
Group type: EXPERIMENTAL
Intervention: Tibolone 2.5 mg/day continuously
Number of subjects: 24
Study 7616869 — intervention group
Group type: COMPARATOR
Intervention: Conjugated equine estrogens 0.625 mg/day combined with medroxyprogesterone acetate 5 mg/day sequentially
Number of subjects: 24
Study 7616869 — intervention group
Group type: EXPERIMENTAL
Intervention: Both tibolone and CEE/MPA
Number of subjects: 24
Study 2167344 — intervention group
Group type: EXPERIMENTAL
Intervention: Breast-feeding
Number of subjects: 176
Study 2167344 — intervention group
Group type: COMPARATOR
Intervention: Bottle-feeding
Number of subjects: 176
Study 7001490 — intervention group
Group type: EXPERIMENTAL
Intervention: pyritinol (800 mg daily)
Number of subjects: 40
Study 7001490 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 40
Study 31141728 — intervention group
Group type: EXPERIMENTAL
Intervention: Sequential DL‐PDT plus IM
Number of subjects: 43
Study 31141728 — intervention group
Group type: COMPARATOR
Intervention: 2 sessions of DL‐PDT
Number of subjects: 43
Study 31141728 — intervention group
Group type: EXPERIMENTAL
Intervention: DL‐PDT plus IM
Number of subjects: 43
Study 28182793 — intervention group
Group type: EXPERIMENTAL
Intervention: SIE (4 x 30 second Wingate sprints)
Number of subjects: 8
Study 28182793 — intervention group
Group type: EXPERIMENTAL
Intervention: HIIE (5 x 4 minutes at 75% Wmax)
Number of subjects: 8
Study 28182793 — intervention group
Group type: EXPERIMENTAL
Intervention: All exercise protocols
Number of subjects: 8
Study 28182793 — intervention group
Group type: EXPERIMENTAL
Intervention: CMIE (30 minutes at 50% of Wmax)
Number of subjects: 8
Study 26426836 — intervention group
Group type: EXPERIMENTAL
Intervention: Narrow Band Imaging (NBI)
Number of subjects: 579
Study 26426836 — intervention group
Group type: COMPARATOR
Intervention: High-Definition White Light Endoscopy (HD-WLE)
Number of subjects: 579
Study 23374411 — intervention group
Group type: EXPERIMENTAL
Intervention: SU-TEm: etch‐and‐rinse + moist dentin
Number of subjects: 39
Study 23374411 — intervention group
Group type: EXPERIMENTAL
Intervention: SU-TEd: etch‐and‐rinse + dry dentin
Number of subjects: 39
Study 23374411 — intervention group
Group type: EXPERIMENTAL
Intervention: SU-SEet: selective enamel etching
Number of subjects: 39
Study 23374411 — intervention group
Group type: EXPERIMENTAL
Intervention: SU-SE: self‐etch
Number of subjects: 39
Study 23374411 — intervention group
Group type: EXPERIMENTAL
Intervention: SU-SE
Number of subjects: 39
Study 23374411 — intervention group
Group type: EXPERIMENTAL
Intervention: SU-TEm
Number of subjects: 39
Study 23374411 — intervention group
Group type: EXPERIMENTAL
Intervention: SU-TEd
Number of subjects: 39
Study 23374411 — intervention group
Group type: EXPERIMENTAL
Intervention: SU-SEet
Number of subjects: 39
Study 17542150 — intervention group
Group type: EXPERIMENTAL
Intervention: Apricitabine (ATC) 1,200 mg/day
Number of subjects: 0
Study 17542150 — intervention group
Group type: EXPERIMENTAL
Intervention: Apricitabine (ATC) 1,600 mg/day
Number of subjects: 0
Study 17542150 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 15581204 — intervention group
Group type: EXPERIMENTAL
Intervention: Mycobacterium vaccae (SRL172) immunotherapy
Number of subjects: 1018
Study 15581204 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1018
Study 10811855 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose aspirin
Number of subjects: 0
Study 10811855 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibuprofen
Number of subjects: 0
Study 10811855 — intervention group
Group type: EXPERIMENTAL
Intervention: Celecoxib
Number of subjects: 0
Study 10811855 — intervention group
Group type: COMPARATOR
Intervention: Control (Placebo)
Number of subjects: 0
Study 10811855 — intervention group
Group type: EXPERIMENTAL
Intervention: LPS
Number of subjects: 0
Study 8636652 — intervention group
Group type: EXPERIMENTAL
Intervention: L-glutamine, 4 gm swish and swallow twice a day, from day 1 of chemotherapy for 28 days or for 4 days past the resolution of any post-chemotherapy mucositis
Number of subjects: 14
Study 1558421 — intervention group
Group type: COMPARATOR
Intervention: RYGB-1 (defunctionalized jejunum 75 cm)
Number of subjects: 45
Study 1558421 — intervention group
Group type: EXPERIMENTAL
Intervention: RYGB-2 (defunctionalized jejunum 150 cm)
Number of subjects: 45
Study 1558421 — intervention group
Group type: EXPERIMENTAL
Intervention: Both RYGB-1 and RYGB-2
Number of subjects: 45
Study 4018423 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous subcutaneous insulin infusion (CSII)
Number of subjects: 30
Study 4018423 — intervention group
Group type: COMPARATOR
Intervention: Unchanged conventional treatment (UCT)
Number of subjects: 30
Study 30500939 — intervention group
Group type: EXPERIMENTAL
Intervention: Personalized peptide vaccination (PPV)
Number of subjects: 88
Study 30500939 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 88
Study 30500939 — intervention group
Group type: EXPERIMENTAL
Intervention: Personalized peptide vaccination (PPV) with SART2‐93 selection
Number of subjects: 88
Study 28958324 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-reported exercise (measured in metabolic equivalents of task hours/week)
Number of subjects: 15486
Study 25424601 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D3-fortified doogh (FD; containing 500 IU/250 ml)
Number of subjects: 100
Study 25424601 — intervention group
Group type: COMPARATOR
Intervention: Plain doogh (PD; containing 150 mg calcium and no vitamin D/250 ml)
Number of subjects: 100
Study 23627921 — intervention group
Group type: EXPERIMENTAL
Intervention: Dry-stored dialyzer with low blood level in the venous chamber (DL)
Number of subjects: 20
Study 23627921 — intervention group
Group type: EXPERIMENTAL
Intervention: Dry-stored dialyzer with high blood level in the venous chamber (DH)
Number of subjects: 20
Study 23627921 — intervention group
Group type: COMPARATOR
Intervention: Wet-stored dialyzer with high blood level (WH)
Number of subjects: 20
Study 21140164 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant human growth hormone (rhGH) 1 mg/day for 7 days
Number of subjects: 30
Study 21140164 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 20201179 — intervention group
Group type: EXPERIMENTAL
Intervention: Rocuronium 0.1 mg/kg
Number of subjects: 60
Study 20201179 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 16966313 — intervention group
Group type: EXPERIMENTAL
Intervention: Manual Muscle Test (MMT) using a 0 to 10-point scale for intra-rater reliability
Number of subjects: 19
Study 16966313 — intervention group
Group type: EXPERIMENTAL
Intervention: Manual Muscle Test (MMT) using a 0 to 10-point scale for inter-rater reliability
Number of subjects: 19
Study 16137053 — intervention group
Group type: EXPERIMENTAL
Intervention: Group A (TV = 7 ml/kg, f=12 bpm)
Number of subjects: 30
Study 16137053 — intervention group
Group type: COMPARATOR
Intervention: Group B (TV=5 ml/kg, f=15 bpm)
Number of subjects: 30
Study 16137053 — intervention group
Group type: COMPARATOR
Intervention: Group C (TV=7 ml/kg, f=15 bpm)
Number of subjects: 30
Study 10895409 — intervention group
Group type: EXPERIMENTAL
Intervention: Adenosine (20 mg/10 min)
Number of subjects: 20
Study 10895409 — intervention group
Group type: COMPARATOR
Intervention: Control (saline)
Number of subjects: 20
Study 9090646 — intervention group
Group type: EXPERIMENTAL
Intervention: Immunoscintigraphy (ISG) with anti-225.28S
Number of subjects: 36
Study 9090646 — intervention group
Group type: EXPERIMENTAL
Intervention: Histology
Number of subjects: 36
Study 9090646 — intervention group
Group type: EXPERIMENTAL
Intervention: Immunohistochemistry
Number of subjects: 36
Study 8222787 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluticasone propionate 50, 100, 200, and 400 micrograms twice daily
Number of subjects: 672
Study 8222787 — intervention group
Group type: COMPARATOR
Intervention: Beclomethasone dipropionate 200 micrograms twice daily
Number of subjects: 672
Study 3513105 — intervention group
Group type: EXPERIMENTAL
Intervention: Nebulized beclomethasone dipropionate (BDP) for 2 weeks
Number of subjects: 9
Study 3513105 — intervention group
Group type: COMPARATOR
Intervention: Placebo for 2 weeks
Number of subjects: 9
Study 3513105 — intervention group
Group type: EXPERIMENTAL
Intervention: Nebulized albuterol (Salbutamol)
Number of subjects: 9
Study 31752498 — intervention group
Group type: EXPERIMENTAL
Intervention: Dosing practices based on current recommendations (46%-76% adherence)
Number of subjects: 230
Study 31752498 — intervention group
Group type: EXPERIMENTAL
Intervention: Lean body weight for dosing propofol, non-depolarising muscle relaxants, sugammadex, and opioids
Number of subjects: 230
Study 31752498 — intervention group
Group type: EXPERIMENTAL
Intervention: Total body weight for dosing suxamethonium
Number of subjects: 230
Study 31752498 — intervention group
Group type: EXPERIMENTAL
Intervention: Use of resources to assist dosing practices in obesity
Number of subjects: 230
Study 31752498 — intervention group
Group type: EXPERIMENTAL
Intervention: Increased incidences of adverse events related to drug dosing
Number of subjects: 230
Study 29659887 — intervention group
Group type: EXPERIMENTAL
Intervention: Aleglitazar
Number of subjects: 4303
Study 29659887 — intervention group
Group type: EXPERIMENTAL
Intervention: Change in HOMA-IR on study treatment
Number of subjects: 4303
Study 29659887 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 4303
Study 27598803 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose external beam radiation therapy (EBRT) up to 80 Gy plus androgen deprivation therapy (ADT) for 2 to 3 years
Number of subjects: 69
Study 24670328 — intervention group
Group type: EXPERIMENTAL
Intervention: 200g beetroot-enriched bread (1.1 mmol nitrate)
Number of subjects: 14
Study 24670328 — intervention group
Group type: COMPARATOR
Intervention: Control bread (no beetroot; 0.01 mmol nitrate)
Number of subjects: 14
Study 22939852 — intervention group
Group type: EXPERIMENTAL
Intervention: Saphenous vein
Number of subjects: 224
Study 22939852 — intervention group
Group type: COMPARATOR
Intervention: Right internal thoracic artery
Number of subjects: 224
Study 22939852 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 224
Study 20230451 — intervention group
Group type: EXPERIMENTAL
Intervention: Essential oxygen oil (OxyRub)
Number of subjects: 505
Study 18602921 — intervention group
Group type: EXPERIMENTAL
Intervention: Granulocyte/monocyte apheresis (n = 112)
Number of subjects: 168
Study 18602921 — intervention group
Group type: COMPARATOR
Intervention: Sham apheresis (n = 56)
Number of subjects: 168
Study 18602921 — intervention group
Group type: EXPERIMENTAL
Intervention: Granulocyte/monocyte apheresis
Number of subjects: 168
Study 18602921 — intervention group
Group type: COMPARATOR
Intervention: Sham apheresis
Number of subjects: 168
Study 15798459 — intervention group
Group type: EXPERIMENTAL
Intervention: Complete clamping (CC)
Number of subjects: 80
Study 15798459 — intervention group
Group type: COMPARATOR
Intervention: Selective clamping (SC)
Number of subjects: 80
Study 15798459 — intervention group
Group type: EXPERIMENTAL
Intervention: Both techniques
Number of subjects: 80
Study 14564429 — intervention group
Group type: EXPERIMENTAL
Intervention: Desmopressin nasal spray (test preparation)
Number of subjects: 32
Study 10702965 — intervention group
Group type: EXPERIMENTAL
Intervention: Grapefruit juice (GFJ)
Number of subjects: 0
Study 10702965 — intervention group
Group type: COMPARATOR
Intervention: Water (control)
Number of subjects: 0
Study 8773862 — intervention group
Group type: EXPERIMENTAL
Intervention: Isoflurane at MAC 1
Number of subjects: 10
Study 8773862 — intervention group
Group type: EXPERIMENTAL
Intervention: Isoflurane at MAC 1.5
Number of subjects: 10
Study 8773862 — intervention group
Group type: COMPARATOR
Intervention: Control (preoperative measurements)
Number of subjects: 10
Study 1831987 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxorubicin
Number of subjects: 0
Study 1831987 — intervention group
Group type: EXPERIMENTAL
Intervention: Daunorubicin
Number of subjects: 0
Study 1831987 — intervention group
Group type: EXPERIMENTAL
Intervention: Epirubicin
Number of subjects: 0
Study 1831987 — intervention group
Group type: EXPERIMENTAL
Intervention: ICRF-187
Number of subjects: 0
Study 1831987 — intervention group
Group type: EXPERIMENTAL
Intervention: Idarubicin
Number of subjects: 0
Study 1831987 — intervention group
Group type: EXPERIMENTAL
Intervention: New anthracycline analogs
Number of subjects: 0
Study 1831987 — intervention group
Group type: EXPERIMENTAL
Intervention: Orally active anthracyclines
Number of subjects: 0
Study 6641534 — intervention group
Group type: EXPERIMENTAL
Intervention: Hepatitis B vaccine (20 micrograms HBs antigen, 3 doses at 0, 1, 6 months)
Number of subjects: 116
Study 6641534 — intervention group
Group type: EXPERIMENTAL
Intervention: Hepatitis B vaccine (40 micrograms HBs antigen, 3 doses at 0, 1, 6 months)
Number of subjects: 116
Study 6641534 — intervention group
Group type: EXPERIMENTAL
Intervention: Hepatitis B vaccine (40 micrograms HBs antigen, 5 doses at 0, 1, 2, 4, 6 months)
Number of subjects: 116
Study 6641534 — intervention group
Group type: EXPERIMENTAL
Intervention: Passive-active vaccination (40 micrograms HBs antigen at 0, 1, 2, 4, 6 months + 3 ml hepatitis B immunoglobulin at 0, 2 months)
Number of subjects: 116
Study 6641534 — intervention group
Group type: EXPERIMENTAL
Intervention: Hepatitis B vaccine (3 doses at 0, 1, 6 months)
Number of subjects: 116
Study 30151903 — intervention group
Group type: EXPERIMENTAL
Intervention: APAP
Number of subjects: 41
Study 30151903 — intervention group
Group type: COMPARATOR
Intervention: APAP + propylene glycol
Number of subjects: 41
Study 29283401 — intervention group
Group type: EXPERIMENTAL
Intervention: Pictorial Dietary Assessment Tool (PDAT)
Number of subjects: 132
Study 29283401 — intervention group
Group type: COMPARATOR
Intervention: modified Comstock
Number of subjects: 132
Study 26465403 — intervention group
Group type: EXPERIMENTAL
Intervention: Injection with saline
Number of subjects: 70
Study 26465403 — intervention group
Group type: EXPERIMENTAL
Intervention: Injection with anesthetic
Number of subjects: 70
Study 26465403 — intervention group
Group type: COMPARATOR
Intervention: Control (non-injected)
Number of subjects: 70
Study 24486242 — intervention group
Group type: EXPERIMENTAL
Intervention: Telephone‐based individual MI counseling plus SM skills group (SM+MI)
Number of subjects: 143
Study 24486242 — intervention group
Group type: COMPARATOR
Intervention: Telephone‐based individual educational counseling plus group education (education control)
Number of subjects: 143
Study 23102084 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-dose cefazolin (1 g) during surgery
Number of subjects: 325
Study 23102084 — intervention group
Group type: COMPARATOR
Intervention: Multiple-dose antimicrobial prophylaxis (5 doses every 12 hours postoperatively)
Number of subjects: 325
Study 19445860 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled fluticasone (375 microg, once daily for 3 months)
Number of subjects: 44
Study 19445860 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 44
Study 17431757 — intervention group
Group type: EXPERIMENTAL
Intervention: Air bubble migration post embryo transfer
Number of subjects: 88
Study 17431757 — intervention group
Group type: EXPERIMENTAL
Intervention: Horizontal position post embryo transfer
Number of subjects: 88
Study 17431757 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound guided embryo placement
Number of subjects: 88
Study 15463883 — intervention group
Group type: EXPERIMENTAL
Intervention: Nebulized colistin sulphate
Number of subjects: 9
Study 15463883 — intervention group
Group type: COMPARATOR
Intervention: Nebulized colistin sulphomethate
Number of subjects: 9
Study 11354303 — intervention group
Group type: EXPERIMENTAL
Intervention: Prosorba column treatment
Number of subjects: 0
Study 11354303 — intervention group
Group type: COMPARATOR
Intervention: Sham column apheresis
Number of subjects: 0
Study 9753292 — intervention group
Group type: EXPERIMENTAL
Intervention: CL 316,243 (1,500 mg/day)
Number of subjects: 14
Study 9753292 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study 7822563 — intervention group
Group type: EXPERIMENTAL
Intervention: Dysthymics
Number of subjects: 3
Study 7822563 — intervention group
Group type: EXPERIMENTAL
Intervention: Anhedonics
Number of subjects: 3
Study 7822563 — intervention group
Group type: COMPARATOR
Intervention: Normal controls
Number of subjects: 3
Study 3041815 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefoperazone plus piperacillin
Number of subjects: 243
Study 3041815 — intervention group
Group type: COMPARATOR
Intervention: Moxalactam plus piperacillin
Number of subjects: 243
Study 3041815 — intervention group
Group type: COMPARATOR
Intervention: Ceftazidime plus piperacillin
Number of subjects: 243
Study 3041815 — intervention group
Group type: COMPARATOR
Intervention: Imipenem alone
Number of subjects: 243
Study 3041815 — intervention group
Group type: COMPARATOR
Intervention: Imipenem
Number of subjects: 243
Study 31344188 — intervention group
Group type: EXPERIMENTAL
Intervention: Watsu therapy
Number of subjects: 46
Study 31344188 — intervention group
Group type: COMPARATOR
Intervention: Conventional hydrotherapy
Number of subjects: 46
Study 28747354 — intervention group
Group type: EXPERIMENTAL
Intervention: mentor training
Number of subjects: 150
Study 28747354 — intervention group
Group type: EXPERIMENTAL
Intervention: peer mentoring
Number of subjects: 150
Study 28747354 — intervention group
Group type: EXPERIMENTAL
Intervention: combined mentor training and peer mentoring
Number of subjects: 150
Study 28747354 — intervention group
Group type: COMPARATOR
Intervention: control condition (usual practice of mentoring)
Number of subjects: 150
Study 25590673 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorella vulgaris supplement for 2 weeks
Number of subjects: 6
Study 23435765 — intervention group
Group type: EXPERIMENTAL
Intervention: VA healthcare use among PTSD-positive women veterans
Number of subjects: 3611
Study 23435765 — intervention group
Group type: EXPERIMENTAL
Intervention: Mental healthcare (MHC) service use among PTSD-positive women veterans
Number of subjects: 3611
Study 23435765 — intervention group
Group type: EXPERIMENTAL
Intervention: MHC service use among VA-users
Number of subjects: 3611
Study 23435765 — intervention group
Group type: EXPERIMENTAL
Intervention: MHC service use among VA-nonusers
Number of subjects: 3611
Study 23435765 — intervention group
Group type: EXPERIMENTAL
Intervention: Predictors of MHC use among PTSD-positive women veterans
Number of subjects: 3611
Study 23435765 — intervention group
Group type: EXPERIMENTAL
Intervention: Predictors of nonuse of MHC among PTSD-positive women veterans
Number of subjects: 3611
Study 23435765 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall PTSD prevalence in women veterans
Number of subjects: 3611
Study 22001994 — intervention group
Group type: EXPERIMENTAL
Intervention: Pramipexole (0.7 mg free base, 3 times a day)
Number of subjects: 0
Study 22001994 — intervention group
Group type: EXPERIMENTAL
Intervention: Ropinirole (12 mg, once daily)
Number of subjects: 0
Study 22001994 — intervention group
Group type: COMPARATOR
Intervention: Levodopa/Carbidopa (100/25 mg, 3 times a day)
Number of subjects: 0
Study 17631898 — intervention group
Group type: EXPERIMENTAL
Intervention: Bupropion
Number of subjects: 2890
Study 17631898 — intervention group
Group type: EXPERIMENTAL
Intervention: SSRIs
Number of subjects: 2890
Study 16586360 — intervention group
Group type: EXPERIMENTAL
Intervention: 9-valent conjugate pneumococcal vaccine
Number of subjects: 2715
Study 16586360 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2715
Study 14604310 — intervention group
Group type: EXPERIMENTAL
Intervention: Percutaneous dilatational tracheostomy (PDT)
Number of subjects: 83
Study 14604310 — intervention group
Group type: COMPARATOR
Intervention: Open tracheostomy (OT)
Number of subjects: 83
Study 14604310 — intervention group
Group type: COMPARATOR
Intervention: Both PDT and OT
Number of subjects: 83
Study 10664832 — intervention group
Group type: EXPERIMENTAL
Intervention: Acute tryptophan depletion (ATD)
Number of subjects: 22
Study 10664832 — intervention group
Group type: COMPARATOR
Intervention: Control mix of essential amino acids
Number of subjects: 22
Study 8844631 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous oral conjugated equine estrogen 0.625 mg daily
Number of subjects: 74
Study 8844631 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous transdermal estradiol-17 beta 50 mcg twice weekly
Number of subjects: 74
Study 1324807 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylcobalamin
Number of subjects: 0
Study 6523202 — intervention group
Group type: EXPERIMENTAL
Intervention: Vibratory massage of the uterus
Number of subjects: 303
Study 6523202 — intervention group
Group type: COMPARATOR
Intervention: Control group (no vibromassage)
Number of subjects: 303
Study 2868973 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 micrograms somatostatin analogue
Number of subjects: 6
Study 2868973 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 micrograms somatostatin analogue
Number of subjects: 6
Study 2868973 — intervention group
Group type: COMPARATOR
Intervention: Placebo (isotonic saline)
Number of subjects: 6
Study 31307674 — intervention group
Group type: EXPERIMENTAL
Intervention: PAM-sutured group
Number of subjects: 91
Study 31307674 — intervention group
Group type: COMPARATOR
Intervention: PAM-non-sutured group
Number of subjects: 91
Study 31307674 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 91
Study 29278961 — intervention group
Group type: EXPERIMENTAL
Intervention: Abobotulinumtoxin A (ABO)
Number of subjects: 40
Study 29278961 — intervention group
Group type: COMPARATOR
Intervention: Onabotulinumtoxin A (ONA)
Number of subjects: 40
Study 29278961 — intervention group
Group type: EXPERIMENTAL
Intervention: Both ABO and ONA
Number of subjects: 40
Study 26685773 — intervention group
Group type: EXPERIMENTAL
Intervention: Risk prediction model for physical functioning
Number of subjects: 489
Study 26685773 — intervention group
Group type: EXPERIMENTAL
Intervention: Risk prediction model for psychological functioning
Number of subjects: 489
Study 24964294 — intervention group
Group type: EXPERIMENTAL
Intervention: Facebook intervention with health coach moderation and self-regulatory techniques
Number of subjects: 404
Study 24964294 — intervention group
Group type: EXPERIMENTAL
Intervention: Facebook posts (polls and photos)
Number of subjects: 404
Study 24964294 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall engagement over time
Number of subjects: 404
Study 24964294 — intervention group
Group type: EXPERIMENTAL
Intervention: Passive engagement
Number of subjects: 404